A tissue-based molecular test used by researchers as part of the STAMPEDE prostate cancer clinical trial helped to identify which patients would benefit from abiraterone treatment.

The ground-breaking University College London-led STAMPEDE clinical trial has shown that adding the hormone therapy abiraterone to the standard treatment for men with high-risk, localised prostate cancer could halve the risk of death from the disease and slow overall progression. 

Prostate cancer is the most commonly diagnosed cancer in the UK. But this type of cancer does not behave the same way in each patient. Consequently, doctors have long experienced difficulties with identifying patients who would benefit from more intensive treatment, and those who could do just as well without it. When a patient with prostate cancer is treated more aggressively than necessary, this is associated with increased side effects and poorer quality of life.

Predicting outcomes

Researchers at University College London (UCL) wanted to assess whether the Decipher tissue-based molecular test could help to determine which patients would benefit from this more intensive treatment.

Decipher scores were analysed from two datasets – real-world patient data of 27,607 cases (of which 5,956 were analysed for outcomes), and 401 men with non-metastatic prostate cancer randomised within the STAMPEDE abiraterone trial.

Researchers found that higher Decipher scores consistently predicted worse outcomes. For every 0.1 increase in the score, the risk of distant metastasis increased with an adjusted hazard ratio of 1.49, and the risk of dying of prostate cancer had a hazard ratio of 1.38. 

“For men with very high-risk prostate cancer, preventing the cancer from spreading is critical, and understanding who benefits most from additional treatment can make a meaningful difference,” said Sarah Howlett, the study’s lead researcher at the UCL Cancer Institute. 

“Our findings suggest that a genomic test could help personalise treatment. Men with high-risk disease but a low Decipher score have low rates of cancer spread, and could potentially be spared more intensive treatment, while men with a high score would be prioritised for it.” 

By showing the same pattern in both a large real-world dataset and a randomised clinical trial, this strengthens the findings, she added, but further validation in other datasets is needed before the test could be used routinely to make treatment decisions.

A first for the UK – AI prostate cancer doctor

A charity in Wales has launched the first AI prostate doctor in the UK. Prostate Cymru is optimistic it could help thousands of men to come forward who might be experiencing symptoms or may want to better understand their risk. But the charity has said it is not just a generic chatbot.

“It has been rigorously trained on current guidelines from NICE, NHS Wales and Public Health bodies,” said Owen Pugsley from Prostate Cymru. “This ensures that every piece of advice and information given out is clinically accurate and safe. And behind the scenes, our dedicated team of specialist urological consultants and specialist nurses are monitoring conversations.”

It may have a role in addition to traditional consultations and the diagnostic PSA test, the charity added. “It is a safe, extra resource that can help guide men towards appropriate, professional medical care when necessary,” Pugsley said.